Keyphrases
Glucagon-like
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Receptor Agonist
100%
Protective Effect
100%
A1 Receptor
100%
Liraglutide
23%
Hepatic Fat
23%
Weight Loss
23%
Glucagon-like peptide-1 Receptor (GLP-1R)
23%
Molecular Techniques
11%
Signaling Pathway
11%
Novel Therapeutic Targets
11%
Disease Treatment
11%
Liver
11%
Mouse Model
11%
Hepatic Glucose Production
11%
5% Weight Loss
11%
Patient-independent
11%
Multi-omics Technique
11%
Successful Intervention
11%
Liver Transplantation
11%
Lipid Metabolism Genes
11%
Emergent Treatment
11%
Agonist Binding
11%
Disease Improvement
11%
Omics Techniques
11%
Liver Enzymes
5%
Insulin
5%
Safe Therapy
5%
Khalifa
5%
Differential Metabolites
5%
Non-coding microRNA
5%
Functional Studies
5%
Beneficial Effects
5%
Alcohol
5%
Hepatic Lipid Accumulation
5%
Differentially Expressed
5%
Omics Data
5%
Lipid Accumulation
5%
Public Health Impact
5%
Differentially Expressed Proteins
5%
Biomolecules
5%
Novel Therapies
5%
Protective Mechanism
5%
Obesity Epidemic
5%
High Morbidity
5%
DElncRNAs
5%
Molecular Systems
5%
Glucagon
5%
New Drug Targets
5%
World Population
5%
Metabolic Pathway
5%
Receptor Activation
5%
Lifestyle Modification
5%
High Mortality
5%
Virus
5%
Pharmacotherapy
5%
Associated Comorbidities
5%
Disease-associated
5%
Disease Prevention
5%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Nonalcoholic Fatty Liver
100%
Liraglutide
23%
Tamsulosin
17%
Combination Therapy
11%
Mouse Model
11%
Glucagon
11%
Triacylglycerol
5%
Liver Enzyme
5%
Comorbidity
5%
Ethanol
5%
Glucagon-Like Peptide 1 Receptor
5%
microRNA
5%
Long Untranslated RNA
5%
Medicine and Dentistry
Glucagon-Like Peptide-1 Agonist
100%
Nonalcoholic Fatty Liver
100%
Liraglutide
23%
Tamsulosin
17%
Lipid Storage
11%
Drug Therapy
11%
Signal Transduction
11%
Combination Therapy
11%
Glucagon Like Peptide 1 Receptor
11%
Liver Enzyme
11%
Gluconeogenesis
11%
Liver Transplantation
11%
Long Untranslated RNA
5%
Lifestyle Modification
5%
Metabolism
5%
Triacylglycerol
5%
In Vitro
5%
Glucagon
5%
Metabolite
5%
Lipid Metabolism
5%
microRNA
5%